Previous 10 | Next 10 |
BERKELEY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 17 th ...
Caribou Bioscience press release ( NASDAQ: CRBU ): Q2 GAAP EPS of -$0.44 misses by $0.08 . Revenue of $4.19M (+183.1% Y/Y) beats by $1.33M . For further details see: Caribou Bioscience GAAP EPS of -$0.44 misses by $0.08, revenue of $4.19M beats by $1.33M ...
-- 6-month CR in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial -- -- Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial -- -- CB-011 IND submission planned for Q4 2022 in patients with r/r MM -- ...
Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma are expected b...
Stanley Druckenmiller’s 13F portfolio value decreased from $2.93B to $2.31B this quarter. Duquesne added Teck Resources and Coterra Energy while dropping Alphabet, Carvana, and Palo Alto Networks. They also added a large short position in S&P 500 index through Puts. The...
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...
The following slide deck was published by Caribou Biosciences, Inc. in conjunction with this event. For further details see: Caribou Biosciences (CRBU) Presents CB-010 ANTLER Clinical Data at EHA 2022 - Slideshow
The following slide deck was published by Caribou Biosciences, Inc. in conjunction with this event. For further details see: Caribou Biosciences (CRBU) Corporate Presentation - Slideshow
Recently IPO’ed biotech Caribou Biosciences (NASDAQ:CRBU) posted the biggest intraday decline after the gene-editing firm reported additional early data for its lead candidate CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma. However, SVB Securities defen...
Gainers: Cogent Biosciences (COGT) +89%. Redbox Entertainment (RDBX) +48%. Alpha Tau Medical (DRTS) +23%. Bright Green Corporation (BGXX) +17%. Aridis Pharmaceuticals (ARDS) +18%. Wah Fu Education Group (WAFU) +14%. Powerbridge Technologies (PBTS) +12%. Hycroft Mining Holding Corporation (HYM...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today a...
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...